Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy  by Berg, Anna.-Lena. et al.
Kidney International, Vol. 56 (1999), pp. 1534–1543
Beneficial effects of ACTH on the serum lipoprotein profile
and glomerular function in patients with
membranous nephropathy
ANNA-LENA BERG, PETER NILSSON-EHLE, and MARGRET ARNADOTTIR
Department of Nephrology and Institute of Laboratory Medicine, Department of Clinical Chemistry, Lund University, Lund,
Sweden, and Department of Medicine, National University Hospital, Reykjavik, Iceland
Beneficial effects of ACTH on the serum lipoprotein profile Hyperlipoproteinemia is an integral part of the ne-
and glomerular function in membranous nephropathy. phrotic syndrome [1, 2]. Most investigators report in-
Background. Previous studies have shown that short-term creased serum concentrations of cholesterol, triglycerides,
treatment with adrenocorticotrophic hormone (ACTH) has a
and lipoprotein(a), whereas the change in high-densitystrong and rapid lipid-lowering effect. In this long-term study
lipoprotein (HDL) cholesterol concentration varies be-of nephrotic patients with idiopathic membranous nephropa-
thy, the influence of ACTH on the serum lipoprotein profile tween studies [1, 2]. The atherogenic features of such a
and glomerular function as well as the dose-effect relationship lipoprotein profile may partially explain the increased
was investigated. risk of atherosclerotic vascular disease in nephrotic pa-
Methods. Fourteen patients received ACTH intramuscu-
tients [3]. Moreover, results from experimental studieslarly at increasing doses during 56 days. Serum concentrations
indicate that hyperlipoproteinemia may contribute toof lipids, lipoproteins, and apolipoproteins as well as variables
renal injury [4], thus creating a vicious circle in protein-of glomerular function were analyzed, and the side-effects were
recorded. ACTH treatment, in the estimated optimal dosage, uric renal disease. Consequently, the correction of the
was then continued in five patients with severe steroid-resistant lipoprotein abnormalities may protect against cardiovas-
nephrotic syndrome. In these five patients, the total treatment cular disease and slow down the progression of renalperiod was 12 months, and the follow-up time after discontinu-
functional impairment. Standard lipid-lowering thera-ing treatment was 18 months.
pies operate effectively in nephrotic patients, particularlyResults. Taking both the statistically significant therapeutic
effects and the modest side-effects into consideration, the opti- the hydroxymethylglutaryl coenzyme A reductase inhib-
mal dosage of ACTH was estimated to be 1 mg twice per itors [5]. However, in many cases, serum lipoprotein con-
week. At that dose, reductions by 30 to 60% in the serum centrations are not normalized in spite of such treatment
concentrations of cholesterol, triglycerides, apolipoprotein B,
[5], indicating the need for additional lipid-lowering al-and lipoprotein(a) were observed, whereas the serum concen-
ternatives for this patient category.trations of high-density lipoprotein cholesterol and apolipo-
protein AI rose by 30 to 40%. In addition, the urinary albumin We have reported that short-term administration of ad-
excretion decreased by 90%, and the glomerular filtration rate renocorticotrophic hormone (ACTH) has a pronounced
increased by 25%. Deterioration was observed in all cases lipid-lowering effect in healthy individuals [6, 7], in ste-
when ACTH was discontinued after a treatment duration of
roid-treated patients with renal disease [8], and in hemo-56 days. However, the five patients in whom ACTH therapy
dialysis patients [9]. Almost all of the participants in thewas resumed were still in remission 18 months after discontinu-
previous studies [6–9] responded to ACTH treatmentance of treatment.
Conclusions. In nephrotic patients with idiopathic membra- with a reduction in the serum concentrations of low-
nous nephropathy, treatment with ACTH 1 mg twice per week density lipoprotein (LDL) cholesterol and lipopro-
was associated with significant long-term improvements in se- tein(a), whereas the influence on triglyceride metabolismrum lipoprotein pattern and glomerular function.
was less consistent. The mechanisms behind these phe-
nomena have not been fully elucidated.
This investigation studied the influence of ACTHKey words: adrenocorticotrophic hormone, glomerular filtration rate,
lipoprotein(a), nephrotic syndrome, hyperlipoproteinemia. treatment on the lipoprotein profile and glomerular func-
tion of nephrotic patients with idiopathic membranousReceived for publication November 23, 1998
nephropathy. Additional purposes were to establish theand in revised form May 18, 1999
Accepted for publication May 20, 1999 optimal or near optimal dosage of ACTH and to study
the long-term efficacy of this treatment. 1999 by the International Society of Nephrology
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Table 1. Serum concentrations of lipids, lipoproteins, apolipoproteins, albumin and creatinine as well as urinary protein excretion and
glomerular filtration rates in 14 patients with membranous nephropathy at baseline (Day 0), after ACTH treatment (Day 56) and during
follow-up (Day 70)
Day 0 Day 56 Day 70
Serum cholesterol mmol /liter 6.6 (5.0–12.4) 4.6 (3.9–7.8)a 5.8 (4.4–10)bd
Serum triglycerides mmol /liter 1.70 (1.1–3.3) 1.05 (0.60–1.3)a 1.21 (0.89–1.89)bd
Serum LDL cholesterol mmol /liter 4.5 (2.8–10.1) 2.8 (2.2–5.6)a 3.55 (3.1–7.6)bd
Serum HDL cholesterol mmol /liter 1.27 (0.82–1.85) 1.69 (1.40–2.10)a 1.44 (1.23–1.89)bd
Serum apolipoprotein B g/liter 1.30 (0.97–2.50) 0.90 (0.71–1.56)a 1.08 (0.89–1.89)bd
Serum apolipoprotein AI g/liter 1.41 (1.15–1.92) 1.88 (1.81–2.71)a 1.65 (1.35–1.88)bd
Serum lipoprotein(a) mg/liter 184 (19–1924) 89 (15–887)a 139 (25–1150)cd
Serum albumin g/liter 23 (12–32) 32 (20–36)a 31 (19–35)ad
Serum creatinine lmol /liter 135 (98–314) 94 (90–188)a 110 (98–210)bd
Urinary albumin mg/day 4830 (3660–15877) 605 (120–3320)a 1040 (630–3750)ad
Iohexol clearance ml/min /1.73 m2 43 (20–78) 64 (23–85)a 51 (14–76)d
Data are given as medians (ranges).
aP , 0.001 compared to day 0
bP , 0.01 compared to day 0
cP , 0.05 compared to day 0
dP , 0.001 compared to day 56
METHODS and they had received more treatment (4 patients had
been treated according to the regimen of Ponticelli et alThe study was approved by the Ethic’s Committee of
[11], whereas one had received high-dose prednisoloneLund University. After informed consent, 14 nephrotic
therapy; Table 2), and all were being treated with simvas-patients were recruited. For the sake of homogeneity,
tatin at the study start. One of the patients who onlyonly patients with idiopathic membranous nephropathy,
participated in the dose-finding study had severe urinaryas established by standard criteria [10], were included.
albumin excretion (Table 2). He was not included in theAll 14 patients participated during the first 70 days of
long-term study for psychosocial reasons.the investigation (dose-finding study). They received
ACTH at increasing doses for 56 days. Blood and urine
Follow-upsamples were collected regularly during that period and,
for control purposes, also 14 days after the discontinu- During the dose-finding study, the patients were seen
ance of treatment. A subgroup of five severely nephrotic by a nephrologist once a week. During the long-term
patients was kept on ACTH treatment for up to 12 ACTH treatment, the patients were seen once a month
months and was thereafter followed up for a further 18 and thereafter every three months. The general medical
months (long-term study). examination, always performed by the same nephrologist
(A.L.B.), included measurements of blood pressure and
Patients body weight. Medication was kept unchanged during the
The dose-finding study included 13 male patients and experimental period except for discontinuance of the
one postmenopausal female patient at the median age diuretic and anticoagulant therapy when indicated and
of 58 (32 to 79) years. The time since renal biopsy was of simvastatin after the 13th month.
16 (5 to 21) months. As shown in Table 1, initially the
urinary albumin excretion and serum lipoprotein con- Adrenocorticotrophic hormone treatment
centrations varied widely. The previous treatment for Adrenocorticotrophic hormone was given as the bio-
the renal disease ranged from the regimen described logically active N-terminal peptide ACTH1-24 in a slow-by Ponticelli et al (steroid and chlorambucil treatment
release preparation (Synacthen Depot; CIBA-Geigyalternating every other month for 6 months) [11] to no
AG, Basel, Switzerland). The drug was administered byimmunosuppressive/anti-inflammatory therapy at all
an intramuscular injection at the dose of 1 mg at 8 a.m.(Table 2). At the beginning, all of the patients were
to 9 a.m.being treated with enalapril or losartan. Most of the
The dose of ACTH was increased from one injectionpatients were on diuretic and/or anticoagulant therapy.
every other week to three injections per week during aFive patients received 20 to 40 mg of simvastatin daily
period of eight weeks. The injections were given on days(discussed later in this article), but no patient was pre-
0, 14, 21, 28, 31, 35, 38, 42, 44, 46, 49, 51, 53, and 56. Inscribed steroids.
the five patients who participated in the long-term study,Five male patients at the median age of 59 (57 to 77)
after the ACTH-free period of two weeks, the treatmentyears participated in the long-term study. Compared with
was continued at a dose of 1 mg twice per week. Theirother patients, these had more severe urinary albumin
excretion and more marked hyperlipidemia (Table 3), total treatment period was 12 months.
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Table 2. Urinary albumin excretion (mg/day) before and after primary treatment for idiopathic membranous nephropathy, before ACTH
treatment, after 56 days and 12 months of ACTH treatment as well as 18 months after the discontinuation of ACTH treatment
(30 months)
P.t. ACTH
Primary treatment (P.t.) Before After Before 56 days 12 months 30 months
Ponticelli regimen 6530 6040 7110 995 66 20
Ponticelli regimen 7750 7230 8775 2200 120 110
Ponticelli regimen 11550 12530 13710 3320 815 630
Ponticelli regimen 11950 10955 12720 2530 230 205
High-dose prednisolone 6755 7010 7750 1990 85 75
Low-dose prednisolone 4170 3995 3660 120
Low-dose prednisolone 4660 4220 4530 605
Low-dose prednisolone 5220 4420 4150 490
Low-dose prednisolone 5320 4430 4840 605
Low-dose prednisolone 5410 4520 4820 590
Low-dose prednisolone 14370 13270 15877 3320
No steroid treatment 4110 3990 3680 350
No steroid treatment 4210 4430 3890 450
No steroid treatment 4890 4770 4610 550
The time interval between the tests before and after primary treatment was 7 (range 5 to 9) months. This interval was arbitrarily chosen in those who received
no steroid treatment. High-dose prednisolone treatment refers to maximal dose of 40 mg daily, low-dose prednisolone treatment refers to maximal dose of 10 mg
daily. Nine patients participated only in the first part of the study.
Table 3. Serum concentrations of lipids, lipoproteins, apolipoproteins, albumin and creatinine as well as urinary protein excretion and
glomerular filtration rates in five patients with idiopathic membranous nephropathy at baseline (Month 0), after ACTH treatment
(Month 12) and during follow-up (Month 13 and Month 30)
Month 0 Month 12 Month 13 Month 30
Serum Cholesterol mmol/liter 7.7 (5.4–12.4) 4.4 (3.9–6.4)a 4.8 (4.2–6.6)ab 4.9 (4.2–6.6)ab
Serum triglycerides mmol/liter 1.90 (1.50–3.30) 0.85 (0.70–0.90)a 1.00 (0.90–1.20)a 1.00 (0.80–1.10)a
Serum LDL cholesterol mmol/liter 5.6 (3.5–10.1) 2.5 (2.2–4.9)a 3.1 (2.4–5.1)ab 3.2 (2.4–5.0)ab
Serum HDL cholesterol mmol/liter 1.27 (0.82–1.58) 1.69 (1.35–1.81)a 1.68 (1.30–1.78)ab 1.71 (1.31–1.76)ab
Serum apolipoprotein B g/liter 1.62 (1.21–2.50) 0.87 (0.74–1.25)a 0.99 (0.79–1.35)ab 0.91 (0.79–1.29)a
Serum apolipoprotein AI g/liter 1.61 (1.18–1.67) 1.90 (1.71–2.20)a 1.85 (1.69–1.90)ab 1.87 (1.71–1.90)a
Serum lipoprotein(a) mg/liter 245 (204–1924) 85 (58–310)a 115 (79–320)ab 100 (80–300)a
Serum albumin g/liter 17 (12–19) 37 (34–39)a 37 (36–39)a 40 (38–42)ab
Serum creatinine lmol /liter 130 (98–314) 90 (86–185)a 90 (90–190)a 90 (85–188)a
Urinary albumin mg/day 8775 (7110–13710) 120 (66–815)a 93 (33–650)ab 110 (20–630)a
Iohexol clearance ml/min/1.73 m2 45 (20–61) 56 (22–68)a
Data are given as medians (ranges).
aP , 0.05 compared to month 0
bP , 0.05 compared to month 1
Blood and urine sampling were analyzed, and the amounts in the 24-hour collec-
tions of urine were calculated.In the dose-finding study, blood samples and 24-hour
On days 0, 56, and 70, and in the long-term study partici-urine portions were collected in the morning on days 0,
pants also after 12 months, the glomerular filtration rate3, 7, 14, 21, 28, 35, 42, 49, 56, and 70, that is, 14 days
was estimated as the plasma clearance of iohexol.after the last ACTH injection. In the long-term study,
Cholesterol and triglyceride concentrations were ana-samples were collected once a month up to month 13
lyzed with enzymatic methods (Kodak Ektachem system).and, thereafter, once every third month. The samples
Before determination of cholesterol in HDL, other lipopro-were obtained immediately before the administration of
teins were precipitated with dextran sulfate and MgCl2.ACTH, if scheduled for that day.
LDL cholesterol concentrations were calculated by theAll blood samples were drawn in the fasting state.
Friedewald formula [12], modified for use with SI units.Serum samples were kept frozen at 2208C to allow the
Apolipoprotein AI, apolipoprotein B, and lipoprotein(a)analysis of lipids, lipoproteins, and apolipoproteins in
concentrations were measured using immunoradiome-the same series. Measurements included serum concen-
tric kits from Pharmacia (Uppsala, Sweden). An intra-trations of cholesterol, triglycerides, HDL cholesterol,
assay variation of the above analyses was less than 3%.apolipoprotein AI, apolipoprotein B, lipoprotein(a), cre-
Creatinine and glucose concentrations were measuredatinine, albumin, and cortisol, as well as blood glucose.
The concentrations of albumin and cortisol in urine by enzymatic methods. Proteins in serum and urine were
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Fig. 1. (A and B) Relative changes of lipids,
lipoproteins, and apolipoproteins induced by
short-term ACTH treatment in 14 nephrotic
patients with idiopathic membranous nephrop-
athy. Intramuscular injections of 1 mg of
ACTH are indicated by arrows. Symbols in A
are: (s) serum cholesterol; (h) serum lipopro-
tein(a); (d) serum triglycerides. Symbols in B
are: (j) serum high density lipoprotein; (d)
serum Apo A1; (h) serum Apo B1; (n) serum
low density lipoprotein; (s) low density lipo-
protein/high density lipoprotein.
analyzed by immunoturbidimetry using monospecific anti- test for the paired case. A two-tailed P value of less than
sera from Dako (Copenhagen, Denmark). 0.05 was considered as indicating statistical significance.
Glomerular filtration rate was estimated by a single
sample method with iohexol as a marker [13]. The plasma
RESULTSconcentration of iohexol was analyzed by high-perfor-
The results are shown in Tables 1 to 3 as well as Figuresmance liquid chromatography [13]. The glomerular fil-
1 to 5. Already after one injection of ACTH, serumtration rate was expressed as ml/min/1.73 m2 body surface
concentrations of cholesterol (P , 0.001), triglyceridesarea.
(P , 0.01), LDL cholesterol (P , 0.001), apolipoprotein
Statistical methods B (P , 0.001), and lipoprotein(a) (P , 0.01) fell signifi-
cantly, whereas those of HDL cholesterol (P 5 0.14)Data are presented as medians 6 ranges. Statistical
differences were evaluated by the Wilcoxon’s rank order and apolipoprotein AI (P 5 0.068) tended to rise. After
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Fig. 2. (A and B) Relative changes of plasma
albumin concentration, urinary protein excre-
tion, and glomerular filtration rate induced by
short-term ACTH treatment in 14 nephrotic
patients with idiopathic membranous nephrop-
athy. Symbols in A are: (j) plasma albumin;
(h) urinary a-1-microglobulin; (s) urinary al-
bumin; (d) urinary IgG. Symbols in B are:
(d) glomerular filtration rate; (s) serum cre-
atinine. Intramuscular injections of 1 mg of
ACTH are indicated by arrows.
one injection of ACTH, there were also significant reduc- concentrations of LDL and Lp(a) increased significantly.
However, numerically, these changes were small, andtions in urinary protein excretion (P , 0.001) and serum
creatinine concentrations (P , 0.001). Each increase in they were not accompanied by a deterioration of glomer-
ular function. The dramatic treatment-associated im-the dose of ACTH was followed by further improvement
in these variables. On day 70, that is, 14 days after the provement of the serum lipoprotein profile and urinary
protein excretion was still expressed at the end of thediscontinuance of the dose-finding treatment, there were
signs of deterioration regarding both the lipoprotein pro- observation period.
The treatment was generally well tolerated. Hospitaliza-file and glomerular function (Table 1 and Figs. 1 and 2).
At the end of the long-term ACTH treatment, serum tion was in no case needed during the treatment period.
On three injections per week, three patients reported signslipoprotein profile and variables of glomerular function
were significantly improved as compared with baseline of reversible fluid retention, and two patients experi-
enced alertness, as well as disturbed night sleep. Duringlevels (Tables 2 and 3 and Figures 3 to 5). During the first
month after the ACTH treatment was stopped, serum the long-term ACTH treatment, one patient received
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Fig. 3. (A and B) Relative changes of lipids,
lipoproteins, and apolipoproteins induced by
long-term ACTH treatment in five nephrotic
patients with idiopathic membranous nephrop-
athy. After 56 days, ACTH treatment was
stopped. Fourteen days later, the treatment
was resumed and continued up to one year.
Symbols in A are: (s) serum cholesterol; (d)
serum triglycerides; (h) serum lipoprotein(a).
Symbols in B are: (j) serum high density lipo-
protein; (d) serum apolipoprotein A1; (h)
serum apolipoprotein B; (n) serum low den-
sity lipoprotein; (s) low density lipoprotein/
high density lipoprotein.
antibiotic treatment for pneumonia. The blood pressure a marked improvement in the serum lipoprotein profile.
Moreover, ACTH treatment was associated with pro-and fasting blood glucose concentration were stable
nounced reduction in urinary protein excretion and ele-throughout (data not shown). Most of the patients needed
vation of glomerular filtration rate in all cases. Takingpotassium supplementation at some time point.
both the therapeutic effects and the modest side-effectsThe changes in the lipoprotein profile were more pro-
of ACTH into consideration, 1 mg twice per week ap-nounced at a dose of three injections per week than two
peared to be the optimal dose.injections per week (Fig. 1). However, the combined
Patients on long-term steroid treatment manifestedpattern of therapeutic effects and side-effects seemed to
increased concentrations of low-density (LDL) and verybe optimal at a dose of two injections per week.
low density lipoproteins (VLDL) [14]. In contrast, we
have recently reported that the administration of ACTH
DISCUSSION leads to reductions in the concentrations of these lipo-
Nephrotic patients with idiopathic membranous ne- proteins [6–9]. Short-term treatment studies with ACTH
showed such a response in healthy individuals, in steroid-phropathy responded rapidly to ACTH treatment, with
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Fig. 4. (A and B) Relative changes of plasma
albumin concentration, urinary protein excre-
tion, and glomerular filtration rate induced by
long-term ACTH treatment in five nephrotic
patients with idiopathic membranous nephrop-
athy. After 56 days, ACTH treatment was
stopped. Fourteen days later, treatment was
resumed and continued up to one year. Sym-
bols in A are: (j) plasma albumin; (h) urinary
a-1-microglobulin; (d) urinary albumin; (s)
urinary IgG. Symbols in B are: (d) glomerular
filtration rate; (s) serum creatinine.
treated patients with kidney disease, and in hemodialysis [7, 16] and a down-regulation of the hepatic lipase activ-
ity [17].patients [6–9]. Moreover, ACTH treatment induced an
increase in serum HDL cholesterol concentration and In this investigation, the effect of ACTH treatment
on the serum lipoprotein pattern of nephrotic patientsa reduction in serum lipoprotein(a) concentration [15],
effects that were also seen after short-term treatment was studied for the first time. The study was designed
to estimate the optimal dosage of ACTH and the long-with dexamethasone [7]. Thus, ACTH as such seems to
modify the metabolism of apolipoprotein B-containing term efficacy of the treatment. As in previously inves-
tigated subjects, ACTH treatment rapidly induced a pro-lipoproteins, whereas the influence on HDL and lipopro-
tein(a) metabolism may be mediated by steroids. The nounced reduction of the serum concentrations of
cholesterol, triglycerides, apolipoprotein B, and lipopro-mechanisms are not known in detail, but in vitro studies
support the hypothesis that ACTH directly influences tein(a), as well as an elevation of the serum concentra-
tions of HDL cholesterol and apolipoprotein AI. More-hepatic lipoprotein metabolism; in studies with a human
hepatoma cell line (HepG2 cells), the addition of ACTH over, glomerular function improved as evidenced by a
marked decrease in urinary protein excretion and a mod-to the medium induced an up-regulation of LDL uptake
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Fig. 5. Relative changes of serum cortisol
concentration (d) and urinary cortisol excre-
tion (s) induced by short-term ACTH treat-
ment in 14 nephrotic patients with idiopathic
membranous nephropathy. Intramuscular in-
jections of 1 mg of ACTH are indicated by
the arrows.
est elevation of glomerular filtration rates. The beneficial pants nor the controlled, randomized design necessary
to prove such a hypothesis. However, the pronouncedeffects on lipoprotein metabolism and glomerular func-
tion were observed in all patients. improvement of glomerular function was chronologically
clearly associated with ACTH treatment, and it was ob-It is well known that the remission of the nephrotic
syndrome is followed by the amelioration of hyperlipo- served in all study participants, even those who had pre-
viously shown resistance toward combined treatmentproteinemia [18, 19]. Therefore, in this study, the evalua-
tion of the direct influence of ACTH on lipoprotein with steroids and alkylating agents (Table 2). Moreover,
the deterioration associated with discontinuance ofmetabolism was hampered by the unexpected dramatic
regression of the proteinuria in all cases. However, the ACTH treatment in all cases speaks against coincidental
fluctuations in glomerular function. This also suggestsnature, the magnitude, and the time of onset of the lipid-
lowering response was comparable to that previously that the treatment duration of 56 days is insufficient,
although the results from the long-term study indicatereported in healthy individuals and in patients with end-
stage renal disease [6–9]. Thus, it is likely that at least that treatment for 12 months can induce long-lasting
improvement in glomerular function, at least when com-the initial improvement in the serum lipoprotein profile
was caused by the direct effect of ACTH on lipoprotein bined with simvastatin.
The mechanisms behind the effects of ACTH on glo-metabolism. The slight deterioration of the lipoprotein
pattern observed after the long-term treatment was merular function are not clear. The lipid-lowering effect
as such may be of importance in the context. This hypoth-stopped probably demonstrates the general role of ACTH
as a lipid-lowering agent. esis is supported by the large body of experimental evi-
dence linking hyperlipidemia and the progression ofThe treatment of membranous nephropathy is still
a matter of controversy. The results of some studies proteinuric renal disease [4] and by the fact that lipid-
lowering treatment has been reported to induce a reduc-indicated beneficial effects of either steroids [20] or cyto-
toxic agents [21], whereas others did not [22, 23]. Ac- tion of urinary protein excretion [25, 26]. However, lipid-
lowering treatment has not previously been associatedcording to Ponticelli et al, combined therapy, consisting
of alternating treatment with methylprednisolone and with such a dramatic reduction of proteinuria, and in
some studies, there was no reduction at all [27]. There-chlorambucil, prevents end-stage renal disease in one
third of nephrotic patients with membranous nephropa- fore, it seems unlikely that the changes in the lipoprotein
pattern are solely responsible for the glomerular effects.thy in the long run [24]. The results of this study suggest
that the administration of ACTH may be an effective The endogenous steroids induced by ACTH may be bet-
ter suited than exogenous steroids for treatment of mem-treatment alternative for membranous nephropathy. It
is true that the study neither had the number of partici- branous nephropathy. Possibly, there is a beneficial in-
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5. Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid-lowering therapyteraction between the endogenous steroid load and the
in patients with renal disease. Kidney Int 48:188–198, 1995
marked improvement of the lipoprotein profile, includ- 6. Berg AL, Hansson P, Nilsson-Ehle P: ACTH 1-24 decreases
ing the reduced serum lipoprotein(a) concentration. hepatic lipase activities and low density lipoprotein concentrations
in healthy men. J Intern Med 229:201–203, 1991Conceivably, ACTH as such influences glomerular he-
7. Berg AL, Nilsson-Ehle P: Direct effects of ACTH on plasma
modynamics, although there is as yet no laboratory evi- lipoprotein metabolism in man: Studies in vivo and in vitro. Metab-
dence of this action. The moderate increase in the glo- olism 43:90–97, 1994
8. Berg AL, Nilsson-Ehle P: ACTH lowers serum lipids in steroidmerular filtration rate observed in this study may
treated hyperlipidemic patients with kidney disease. Kidney Int
represent improved renal blood flow associated with a 50:538–542, 1996
remission of the nephrotic syndrome. 9. Arnadottir A, Berg AL, Dallongeville J, Fruchart JC, Nils-
son-Ehle P: Adrenocorticotropic hormone lowers serum Lp(a)As expected, the side-effects were those generally as-
and LDL cholesterol concentrations but does not influence triglyc-
sociated with steroids. At the ACTH dose of 1 mg twice eride metabolism in hemodialysis patients. Kidney Int 52:1651–
per week, the patients experienced minimal side-effects, 1655, 1997
10. Ehrenreich T, Porush JG, Churg J, Garfinkel L, Glabman S,whereas the beneficial influence on lipoprotein metabo-
Goldstein MH, Grishman E, Yunis SL: Treatment of idiopathic
lism and glomerular function was operating satisfactorily. membranous nephropathy. N Engl J Med 295:741–746, 1997
Consequently, this dosage was used in the long-term 11. Ponticelli C, Zuchelli P, Imbasciati E, Cagnoli L, Pozzi C,
Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdellistudy. However, cumulative effects may have occurred
M, Locatelli F: Controlled trial of methylprednisolone and chlor-
during the dose-finding study because washout periods ambucil in idiopathic membranous nephropathy. N Engl J Med
between the doses were not applied, and therefore, it is 310:946–950, 1984
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of thepossible that still lower doses of ACTH may give similar
concentration of low-density lipoprotein cholesterol in plasma,
results in the long run. This, in combination with other without use of the preparative ultracentrifuge. Clin Chem 18:499–
endocrinological aspects, awaits further studies. The en- 502, 1972
13. Krutze´n E, Ba¨ck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasmadocrinological approach of this study was limited to mea-
clearance of a new contrast agent, iohexol: A method for the
surements of cortisol in serum and urine, expectedly assessment of glomerular filtration rate. J Lab Clin Med 104:955–
showing increases with increasing dosage of ACTH 961, 1984
14. Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in(Fig. 5).
uremia, dialysis, and transplantation. Kidney Int 19:625–637, 1981
In conclusion, in nephrotic patients with idiopathic 15. Arnadottir M, Berg AL, Kronenberg F, Lingenhel A, Hugos-
membranous nephropathy, treatment with a long-acting son T, Hegbrant J, Nilsson-Ehle P: ACTH-induced reduction
of plasma lipoprotein(a) concentrations in healthy individuals andACTH preparation was associated with a marked im-
hemodialysis patients: Relation to apolipoprotein(a) size polymor-
provement in serum lipoprotein profile and glomerular phism. Metabolism 48:342–346, 1999
function. Because of the dramatic reduction in urinary 16. Bartens W, Kra¨mer-Guth A, Wanner C: Corticotropin increases
the receptor-specific uptake of native low-density lipoproteinprotein excretion, it was difficult to assess the direct lipid-
(LDL)—but not of oxidized LDL and native or oxidized lipopro-
lowering effect of ACTH in this patient category. On tein(a) [Lp(a)]—in HEPG2 cells: No evidence for Lp(a) catabolism
the other hand, the results suggest that ACTH may have via the LDL-receptor. Metabolism 46:726–729, 1997
17. Berg AL, Nilsson-Ehle P: Regulation of hepatic lipase secretiona place in the treatment of idiopathic membranous ne-
from Hep G2 cells by ACTH and corticosteroids. Horm Metab
phropathy. This hypothesis must be tested in a con- Res 29:475–476, 1997
trolled, randomized study. 18. Joven J, Villabona C, Vilella Masana L, Alberti R, Valles
M: Abnormalities of lipoprotein metabolism in patients with the
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